Quarterly report [Sections 13 or 15(d)]

SEGMENT REPORTING - Significant expense categories (Details)

v3.26.1
SEGMENT REPORTING - Significant expense categories (Details) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Operating Expenses:        
Loss from operations $ (12,266,399) $ (10,184,661) $ (20,911,296) $ (17,644,757)
Other income 536,743 67,632 937,267 179,825
Consolidated Net Loss 11,729,656 10,117,029 19,974,029 17,464,932
Life science | Operating segment        
Operating Expenses:        
PMN310 development program costs 7,785,427 8,050,610 14,049,539 12,776,951
Other non-employee research and development costs 310,571 220,669 503,285 498,584
Employee costs 2,916,715 1,053,258 4,030,478 2,496,325
Other general and administrative costs 1,253,686 860,124 2,327,994 1,872,897
Loss from operations 12,266,399 10,184,661 20,911,296 17,644,757
Other income (536,743) (67,632) (937,267) (179,825)
Consolidated Net Loss $ 11,729,656 $ 10,117,029 $ 19,974,029 $ 17,464,932